- Category : Healthcare
- Region : Global
- Publishing Date :
Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity
Global minimal residual disease (MRD) testing market will reach $ 2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region.
Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Services
• Test Kits & Consumables
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Non-Hodgkin's Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
• Multiple Myeloma (MM)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphoblastic Leukemia (CLL)
• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Hodgkin's Lymphoma (HL)
• Solid Tumor
• Other Applications
By Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies
By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals and Clinics
• Research Institutions
• Diagnostic Laboratories
• Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
List of Figures:
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 18
Figure 4. Global Minimal Residual Disease Testing Market, 2021-2031, $ mn 21
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Global Minimal Residual Disease Testing Market 26
Figure 7. World Number of Deaths from Cancers in 201 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Global Minimal Residual Disease Testing Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Global Minimal Residual Disease Testing Market 39
Figure 13. Breakdown of Global Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 44
Figure 14. Global Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 44
Figure 15. Global Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 45
Figure 16. Global Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 46
Figure 17. Breakdown of Global Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 48
Figure 18. Global Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 48
Figure 19. Global Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 49
Figure 20. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 51
Figure 21. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 52
Figure 22. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 53
Figure 23. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 54
Figure 24. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 55
Figure 25. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 56
Figure 26. Global Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 57
Figure 27. Global Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 58
Figure 28. Global Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 59
Figure 29. Global Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 60
Figure 30. Global Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 61
Figure 31. Global Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 62
Figure 32. Global Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 63
Figure 33. Global Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 64
Figure 34. Breakdown of Global Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 66
Figure 35. Global Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 66
Figure 36. Global Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 67
Figure 37. Global Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 68
Figure 38. Global Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 69
Figure 39. Global Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 70
Figure 40. Breakdown of Global Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 72
Figure 41. Global Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 72
Figure 42. Global Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 73
Figure 43. Global Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 74
Figure 44. Global Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 75
Figure 45. Global Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 76
Figure 46. Global Market Snapshot by Region 77
Figure 47. Geographic Spread of Worldwide Minimal Residual Disease Testing Market, 2021-2031, % of Sales Revenue 78
Figure 48. Global Addressable Market Cap in 2022-2031 by Region, Value ($ mn) and Share (%) 79
Figure 49. North American Minimal Residual Disease Testing Market, 2021-2031, $ mn 82
Figure 50. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 83
Figure 51. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 52. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 86
Figure 53. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 88
Figure 54. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 90
Figure 55. European Minimal Residual Disease Testing Market, 2021-2031, $ mn 93
Figure 56. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 94
Figure 57. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 95
Figure 58. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn 96
Figure 59. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn 98
Figure 60. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn 100
Figure 61. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn 102
Figure 62. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn 104
Figure 63. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn 106
Figure 64. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn 108
Figure 65. Asia-Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn 111
Figure 66. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 111
Figure 67. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 113
Figure 68. Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn 115
Figure 69. Minimal Residual Disease Testing Market in China, 2021-2031, $ mn 117
Figure 70. Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn 119
Figure 71. Minimal Residual Disease Testing Market in India, 2021-2031, $ mn 121
Figure 72. Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn 123
Figure 73. Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn 125
Figure 74. South America Minimal Residual Disease Testing Market, 2021-2031, $ mn 128
Figure 75. Breakdown of South America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 128
Figure 76. Contribution to South America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 129
Figure 77. Minimal Residual Disease Testing Market in Argentina, 2021-2031, $ mn 130
Figure 78. Minimal Residual Disease Testing Market in Brazil, 2021-2031, $ mn 132
Figure 79. Minimal Residual Disease Testing Market in Chile, 2021-2031, $ mn 134
Figure 80. Minimal Residual Disease Testing Market in Rest of South America, 2021-2031, $ mn 136
Figure 81. Minimal Residual Disease Testing Market in Middle East and Africa (MEA), 2021-2031, $ mn 138
Figure 82. Breakdown of MEA Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 138
Figure 83. Contribution to MEA 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 84. Minimal Residual Disease Testing Market in UAE, 2021-2031, $ mn 140
Figure 85. Minimal Residual Disease Testing Market in Saudi Arabia, 2021-2031, $ mn 142
Figure 86. Minimal Residual Disease Testing Market in South Africa, 2021-2031, $ mn 144
Figure 87. Growth Stage of Global Minimal Residual Disease Testing Industry over the Forecast Period 147